# EU-1-14-963_public-assessment-report_20141205_20141205_brimica-genuair-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
25 September 2014
EMA/CHMP/717942/2014
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Brimica Genuair
International non-proprietary name: Aclidinium bromide/ Formoterol fumarate
dihydrate
Procedure No. EMEA/H/C/003969/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.
Administrative information
Name of the medicinal product:
Brimica Genuair
Applicant:
Almirall S.A
Ronda General Mitre, 151
08022 Barcelona
Spain
Active substance:
Aclidinium bromide/Formoterol fumarate
dihydrate
International Nonproprietary Name/Common
Name:
Aclidinium bromide/Formoterol fumarate
dihydrate
Pharmaco-therapeutic group
(ATC Code):
Drugs for obstructive airway diseases
(R03AL05)
Therapeutic indication:
Brimica Genuair is indicated as a maintenance
bronchodilator treatment for airflow
obstruction and relief of symptoms in adult
patients with chronic obstructive pulmonary
disease (COPD).
Pharmaceutical form:
Inhalation powder
Strengths:
340 ug / 12 ug
Route of administration:
Inhalation use
Packaging:
Inhaler (plastic/stainless steel)
Package sizes:
1 inhaler with 60 actuations and 3 inhalers with
60 actuations
Assessment report
EMA/CHMP/717942/2014
Page 2/136
